scispace - formally typeset
C

Chris Logothetis

Researcher at University of Texas MD Anderson Cancer Center

Publications -  5
Citations -  1667

Chris Logothetis is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Prostate cancer & Downregulation and upregulation. The author has an hindex of 5, co-authored 5 publications receiving 1307 citations. Previous affiliations of Chris Logothetis include National and Kapodistrian University of Athens.

Papers
More filters
Journal ArticleDOI

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

TL;DR: This work identifies induction of glucocorticoid receptor (GR) expression as a common feature of drug-resistant tumors in a credentialed preclinical model and establishes a mechanism of escape from AR blockade through expansion of cells primed to drive AR target genes via an alternative nuclear receptor upon drug exposure.
Journal ArticleDOI

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen, +60 more
- 01 Feb 2018 - 
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Silke Gillessen, +80 more
- 01 Apr 2020 - 
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
Journal ArticleDOI

Neoadjuvant and adjuvant chemotherapy in advanced disease--what are the effects on survival and prognosis?

TL;DR: This paper will attempt to address some of the important issues and questions surrounding the combination of chemotherapy and definitive local therapy in the treatment of muscle-invasive bladder cancer.